Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation
Critical Care2006Vol. 10(1), pp. R26–R26
Citations Over TimeTop 10% of 2006 papers
Christophe Mariat, C. Venet, F. Jehl, Sandrine Mwewa, Lazarevic Vesna, Éric Diconne, Nathalie Fonsale, Anne Carricajo, Stéphane Guyomarch, Régine Vermesch, G. Aubert, Roselyne Bidault, Jean-Claude Bertrand, Fabrice Zéni
Abstract
We conclude that a dosing regimen of 3 g/day ceftazidime, by continuous infusion, following a 2 g loading dose, results in serum concentrations more than four times the minimum inhibitory concentration for all susceptible pathogens, and we recommend this regimen in critically ill patients undergoing CVVHDF.
Related Papers
- → Aspects of clinical trials with ceftazidime worldwide(1985)11 cited
- Economic Evaluation of Domestic and Imported Ceftazidime in the Treatment of Acute Pneumonia(2012)
- Antibacterial Effect of Cephalothin on ESBLs-producing K.Pneunmoniae(2006)
- Study on ceftazidime-induced endotoxin release in Escherichia coli and anti-endotoxin effect of Chinese medicine injections in vitro(2008)
- Clinical observation on the therapeutic effect of ceflazidime for injection on 80 patients infected with bacterial diseases.(2006)